Key facts
- Nuance Pharma’s last known valuation is $623.1M (Jul 2025).
- It has raised $305.8M; the latest was Later Stage VC ($41.8M) in Jul 2025.
- Notable investors include Shun Xi Fund, RTW Investments, HBM Partners, Chang Development, Beijing Konruns Pharmaceutical Company — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Nuance Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Nuance Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nuance Pharma
Operator of a biopharma platform intended to address critical unmet needs in the Asia Pacific region. The company focuses on late-stage clinical pipeline and commercial stage asset portfolio across respiratory, emergency care, iron deficiency anaemia and pain management, thereby providing innovative drug development solutions for hospitals.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2014
- Employees
- 287
- Website
- nuancepharma.com/
- Ownership
- Privately Held (backing)
Nuance Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nuance Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nuance Pharma in its N-PORT filings yet. We sweep new filings monthly.